Table 1.
Baseline and follow-up characteristics for study sample (n = 24 107) compared to patients not included in the analysis (n = 9708).
| Variables | Patients excluded | Study sample |
|---|---|---|
| Total number of patients | 9708 | 24107 |
| Baseline CD4 cell count (cells/μl) | ||
| Median (IQR) | 183 (82–336) | 144 (61–235) |
| Unknown (%) | 7288 (75.1) | – |
| Age at baseline (years) | ||
| Median (IQR) | 36.7 (30.7–43.7) | 36.3 (30.5–43.2) |
| Unknown (%) | 1714 (17.7) | – |
| <25 years (%) | 558 (5.8) | 1486 (6.2) |
| 25–29 | 1166 (12.0) | 3885 (16.1) |
| 30–34 | 1621 (16.7) | 5192 (21.5) |
| 35–39 | 1716 (17.7) | 4939 (20.5) |
| 40–45 | 1184 (12.2) | 3716 (15.4) |
| 45–50 | 835 (8.6) | 2459 (10.2) |
| 50–54 | 490 (5.1) | 1370 (5.7) |
| ≥55 | 424 (4.4) | 1060 (4.4) |
| Sex (%) | ||
| Women | 5804 (59.8) | 15322 (63.6) |
| Men | 3457 (35.6) | 8785 (36.4) |
| Unknown | 447 (4.6) | – |
| Baseline clinical stage (%) | ||
| CDC stage A, B, WHO I, II | 3796 (39.1) | 10637 (44.1) |
| AIDS stage, WHO III, IV | 3036 (31.3) | 9702 (40.2) |
| Unknown | 2876 (29.6) | 3768 (15.7) |
| Year of ART initiation (%) | ||
| Prior to 2004 | 847 (8.7) | 1683 (7.0) |
| 2004 to 2009 | 8521 (87.8) | 22424 (93.0) |
| Unknown | 340 (3.5) | – |
| Initial ART regimen (%) | ||
| NNRTI-based | 7804 (80.4) | 20938 (86.9) |
| PI-based | 700 (7.2) | 1331 (5.5) |
| Others | 750 (7.7) | 1739 (7.2) |
| Unknown | 454 (4.7) | 99 (0.4) |
| Follow-up characteristics | ||
| Died (%) | 188 (1.9) | 779 (3.2) |
| Lost to follow-up (%) | 2602 (26.8) | 5690 (23.6) |
| Number of CD4 measurements | 8915 | 50893 |
| Median number of CD4 measurements (IQR) | 0 (0–2) | 2 (1–3) |
IeDEA West Africa Collaboration.
ART, antiretroviral treatment; CDC, Centers for Disease Control; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.